secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvectis Pharma, Inc. (NVCT)
CIK:        0001875558
Form:       8-K
Filed at:   2023-07-03T23:59:59+00:00
Accession:  0001104659-23-077410
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 2.02
LLM model:  deepseek-v4-flash:cloud@v2

Nuvectis Pharma reports $24.5M cash, runway into H1 2025
--------------------------------------------------------

- Cash and equivalents of $24.5M at June 30, 2023, up ~$9.0M from March 31, 2023.
- Increase primarily from exercise of previously issued preferred investment options in Q2 2023.
- Company estimates current cash sufficient to fund planned operations into first half of 2025.
- Cash figure is preliminary, subject to change upon completion of period-end close.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1875558/000110465923077410/0001104659-23-077410-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1875558/000110465923077410/tm2320415d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-077410

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer